Atticus Wealth Management LLC Boosts Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Atticus Wealth Management LLC raised its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 56.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,762 shares of the company’s stock after acquiring an additional 17,199 shares during the period. Atticus Wealth Management LLC owned approximately 0.06% of Tenaya Therapeutics worth $68,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Synovus Financial Corp acquired a new position in Tenaya Therapeutics in the 3rd quarter worth approximately $28,000. The Manufacturers Life Insurance Company raised its holdings in shares of Tenaya Therapeutics by 43.2% during the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after purchasing an additional 7,000 shares during the last quarter. Algert Global LLC acquired a new position in Tenaya Therapeutics during the second quarter valued at $74,000. SG Americas Securities LLC purchased a new stake in Tenaya Therapeutics in the third quarter valued at $49,000. Finally, XTX Topco Ltd grew its position in Tenaya Therapeutics by 51.2% during the 3rd quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after purchasing an additional 16,687 shares during the period. 90.54% of the stock is owned by hedge funds and other institutional investors.

Tenaya Therapeutics Stock Performance

NASDAQ TNYA opened at $1.21 on Monday. Tenaya Therapeutics, Inc. has a 1-year low of $0.99 and a 1-year high of $7.01. The stock’s 50 day simple moving average is $2.12 and its 200-day simple moving average is $2.37.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07. As a group, sell-side analysts forecast that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on TNYA shares. Leerink Partners restated an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a report on Friday, October 18th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a report on Tuesday, January 14th. Piper Sandler restated an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Chardan Capital restated a “buy” rating and issued a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Wednesday, December 18th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $17.33.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.